High-Level Overview
2Flo Ventures is a startup studio and venture capital firm dedicated to accelerating equitable innovation in healthcare. Its mission centers on investing in and building companies that address large unmet medical needs, with a strong emphasis on health equity and inclusion. The firm’s investment philosophy prioritizes diverse healthcare entrepreneurs and startups developing therapeutics, medical devices, diagnostics, and digital health solutions—particularly those focused on closing gaps in health outcomes for underserved communities. 2Flo Ventures typically invests at the pre-seed to Series A stages, supporting early-stage companies that aim to drive meaningful impact in biotechnology and digital health. By combining venture capital with hands-on startup studio support, 2Flo plays a pivotal role in shaping a more inclusive and innovative healthcare ecosystem.
Origin Story
Founded in 2021, 2Flo Ventures emerged from a recognition that systemic disparities in healthcare require targeted investment and operational support. The firm was established by a team of experienced healthcare investors and operators, including Managing Partner Paul Burton, who brings over two decades of experience in corporate finance, strategic advisory, and venture capital. Other key partners include Dr. Charlotte Jones-Burton and Lyle Berkowitz, both of whom have deep backgrounds in healthcare innovation and entrepreneurship. Since its inception, 2Flo has evolved from a traditional VC model into a hybrid startup studio, actively co-founding and scaling companies while also investing in external startups. This dual approach allows 2Flo to not only fund innovation but also directly shape the development of impactful health technologies.
Core Differentiators
- Hybrid Startup Studio & VC Model: 2Flo Ventures uniquely combines venture capital with hands-on startup studio resources, enabling it to co-found, incubate, and scale companies from the ground up.
- Focus on Health Equity: The firm is committed to investing in diverse founders and solutions that specifically address disparities in healthcare access and outcomes.
- Sector Specialization: 2Flo concentrates on biotechnology, medical devices, diagnostics, and digital health, with a particular interest in therapeutics and platforms that serve underserved populations.
- Impact Measurement: Partnering with impact advisors like Propelevate, 2Flo integrates robust impact strategy, measurement, and reporting into its investment process, aligning with industry standards and amplifying its mission-driven approach.
- Strong Network & Operating Support: The firm leverages its partners’ extensive networks in healthcare, finance, and technology to provide portfolio companies with strategic guidance, operational expertise, and access to key stakeholders.
Role in the Broader Tech Landscape
2Flo Ventures is riding the growing trend of mission-driven investing in healthcare, where impact and financial returns are increasingly seen as complementary. The timing is critical, as digital health adoption accelerates and the demand for equitable solutions intensifies in the wake of global health challenges. Market forces—including regulatory shifts, rising healthcare costs, and increased awareness of health disparities—are working in 2Flo’s favor, creating fertile ground for innovative startups that prioritize access and inclusion. By supporting a new generation of health tech entrepreneurs, 2Flo is helping to reshape the healthcare landscape, fostering a more diverse and resilient ecosystem that better serves all communities.
Quick Take & Future Outlook
Looking ahead, 2Flo Ventures is poised to expand its influence as it launches new funds and deepens its impact measurement capabilities. The firm’s hybrid model is likely to attract more founders seeking both capital and operational support, while its focus on health equity positions it at the forefront of a broader movement toward inclusive innovation. As healthcare continues to evolve, 2Flo’s ability to identify and nurture breakthrough technologies—especially those addressing systemic gaps—will be increasingly valuable. The firm’s journey reflects a growing recognition that true innovation in health tech must be both impactful and equitable, setting a new standard for what venture capital can achieve in the sector.